Sec Form 4 Filing - AFEYAN NOUBAR @ BG Medicine, Inc. - 2014-12-03

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person AFEYAN NOUBAR 2. Issuer Name and Ticker or Trading Symbol BG Medicine, Inc. [ BGMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O FLAGSHIP VENTURES, ONE MEMORIAL DRIVE, 7TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 12/03/2014 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/03/2014 X 17,080 A $ 0.02 2,451,880 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/03/2014 S( 2 ) 616 D $ 0.46 ( 3 ) 2,451,264 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/03/2014 X 17,080 A $ 0.02 2,468,344 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/03/2014 S( 4 ) 616 D $ 0.46 ( 3 ) 2,467,728 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/03/2014 X 17,080 A $ 0.02 2,484,808 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/03/2014 S( 5 ) 616 D $ 0.46 ( 3 ) 2,484,192 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/04/2014 J( 6 ) 2,484,192 D $ 0 0 I Held by NewcoGen Group LLC ( 1 ) Common Stock 12/04/2014 J( 6 ) 164,528 A $ 0 175,718 D Common Stock 12/04/2014 J( 6 ) 10,029 A $ 0 10,029 I Held by Atlast LP ( 7 ) Common Stock 215,013 I Held by AGTC Advisors Fund, L.P. ( 1 ) Common Stock 2,851,447 I Held by Applied Genomic Technology Capital Fund, L.P. ( 1 ) Common Stock 1,764,286 I Held by Flagship Ventures Fund 2007, L.P. ( 8 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant to Purchase Common Stock (right to buy) $ 0.02 12/03/2014 X 17,080 ( 9 ) 03/30/2020 Common Stock 17,080 $ 0 0 I Held by NewcoGen Group LLC ( 1 ) Warrant to Purchase Common Stock (right to buy) $ 0.02 12/03/2014 X 17,080 ( 9 ) 09/27/2020 Common Stock 17,080 $ 0 0 I Held by NewcoGen Group LLC ( 1 ) Warrant to Purchase Common Stock (right to buy) $ 0.02 12/03/2014 X 17,080 ( 9 ) 11/04/2020 Common Stock 17,080 $ 0 0 I Held by NewcoGen Group LLC ( 1 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other AFEYAN NOUBAR C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X X NEWCOGEN GROUP LLC C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X KANIA EDWIN M JR C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X Flagship Ventures Management, Inc. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X NewcoGen Group, Inc. C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE, MA02142 X Signatures /s/ Noubar Afeyan 12/05/2014 Signature of Reporting Person Date /s/ Noubar Afeyan, Authorized Signatory for NewcoGen Group LLC 12/05/2014 Signature of Reporting Person Date /s/ Edwin M. Kania, Jr. 12/05/2014 Signature of Reporting Person Date /s/ Noubar Afeyan, Authorized Signatory for Flagship Ventures Management, Inc. 12/05/2014 Signature of Reporting Person Date /s/ Noubar Afeyan, Authorized Signatory for NewcoGen Group, Inc. 12/05/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )NewcoGen Group, Inc. ("NG") is the manager of NewcoGen Group LLC ("NGG"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by NGG and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein. ( 2 )On December 3, 2014, NGG exercised a warrant to purchase 17,080 shares of Common Stock for $0.02 per share. NGG exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 616 of the warrant shares to pay the exercise price and issuing to NGG the remaining 16,464 shares. ( 3 )The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date. ( 4 )On December 3, 2014, NGG exercised a warrant to purchase 17,080 shares of Common Stock for $0.02 per share. NGG exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 616 of the warrant shares to pay the exercise price and issuing to NGG the remaining 16,464 shares. ( 5 )On December 3, 2014, NGG exercised a warrant to purchase 17,080 shares of Common Stock for $0.02 per share. NGG exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 616 of the warrant shares to pay the exercise price and issuing to NGG the remaining 16,464 shares. ( 6 )In addition to the cashless exercises of the warrants reported above, this Form 4 is being filed to report a pro-rata distribution by NGG for no consideration to its members. As members of NGG, Noubar Afeyan received 164,528 shares of Common Stock and Atlast LP received 10,029 shares of Common Stock in the distribution. The beneficial ownership of the entities named in this Form 4, other than the Reporting Persons filing this Form 4, did not change as a result of this transaction. ( 7 )Noubar Afeyan is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Mr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. ( 8 )Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein. ( 9 )This warrant is immediately exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.